News
REGMF
9.81
NaN%
--
RemeGen Shareholders Back All Resolutions at 2025 AGM
TipRanks · 2d ago
RemeGen Clarifies Board Composition and Committee Roles
TipRanks · 2d ago
J.P. Morgan Sticks to Their Buy Rating for RemeGen Co. Ltd. Class H (9995)
TipRanks · 06/11 00:27
RemeGen Co. Ltd. Class H (9995) Gets a Buy from UBS
TipRanks · 06/10 00:25
RemeGen Wins Conditional China Nod for Telitacicept in IgA Nephropathy
TipRanks · 06/08 12:45
RemeGen Wins NMPA Approval for New Telitacicept Indication in Sjögren’s Disease
TipRanks · 06/08 12:11
RemeGen boosts cash management with new RMB300 million SPDB wealth product
TipRanks · 06/01 09:13
Morgan Stanley Keeps Their Hold Rating on RemeGen Co. Ltd. Class H (9995)
TipRanks · 05/30 00:41
RemeGen Expands Use of Idle Funds in HTSC Wealth Products
TipRanks · 05/26 08:38
RemeGen Deploys Idle Funds Into HTSC Wealth Products in Discloseable Transaction
TipRanks · 05/20 10:10
RemeGen Sets 2025 AGM to Approve Reports, Capital Changes and New Board
TipRanks · 05/20 10:09
RemeGen Tightens Controls After Delay in Disclosing Wealth Management Deals
TipRanks · 05/19 13:13
RemeGen Deploys Idle Cash into HTSC Wealth Products in Discloseable Deal
TipRanks · 05/19 11:40
RemeGen Launches Election for Third-Session Board as Current Term Nears Expiry
TipRanks · 05/18 14:30
RemeGen Plans Governance and Articles Overhaul Following Share Incentive Issuances
TipRanks · 05/18 13:42
Shenwan Hongyuan Keeps Their Buy Rating on RemeGen Co. Ltd. Class H (9995)
TipRanks · 05/15 08:59
RemeGen Deploys Idle Cash Into RMB453 Million HTSC Wealth Products
TipRanks · 05/14 23:39
RemeGen Commits US$70 Million of Idle Funds to OCBC Structured Deposit
TipRanks · 05/14 10:32
RemeGen Commits RMB1.43 Billion of Idle Funds to Wealth Management Products
TipRanks · 05/13 11:18
RemeGen Co. Ltd. Class H (9995) Gets a Buy from First Shanghai Securities
TipRanks · 05/13 05:27
More
Webull provides a variety of real-time REGMF stock news. You can receive the latest news about Remegen through multiple platforms. This information may help you make smarter investment decisions.
About REGMF
RemeGen Co Ltd is a China-based company principally engaged in biopharmaceutical research, biopharmaceutical service, biopharmaceutical production and sale. The Company focuses on therapeutic antibody drugs such as antibody-drug conjugates (ADC), antibody fusion proteins, monoclonal antibodies and bispecific antibodies. The Company’s main products include telitacicept, disitamab vedotin, RC28-E and others. The Company's products are mainly used to treat major diseases such as autoimmune diseases, oncology and ophthalmology. The Company mainly operates its businesses in the domestic and overseas markets.